Cointime

LevitasBio

company

About

LevitasBio is advancing science and human health by providing researchers with a new and powerful method of cellular analysis.

  • 11 - 50

Highlights

Total Funding Amount
$53M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series B
Last Funding Money Raised
$18M
Industries
Analytics,Biotechnology,Health Diagnostics,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
11 - 50
Operating Status
Active

Levitas is redefining cellular analytics with its novel platform of magnetic levitation technology. Their disruptive technology overcomes the current technological limitations of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses of previously inaccessible, high-value primary samples and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$53M
LevitasBio has raised a total of $53M in funding over 2 rounds. Their latest funding was raised on Oct 24, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 24, 2022 Series C $35M 1 — — Detail
Jan 5, 2021 Series B $18M 1 Thalys Medical Group — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
LevitasBio is funded by 2 investors. Thalys Medical Group and Pavilion Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Thalys Medical Group Yes Series B
Pavilion Capital — Series C
Cointime
Содержание
компания